Showing results (341-350 of 435) with videos related to
Sort By:
Pageof 44
Cancer Discovery|December 3, 2017
Genomic Landscape of Cell-Free DNA in Patients with Colorectal CancerJohn H Strickler, Jonathan M Loree, Leanne G Ahronian, et al.Gastroenterology|January 20, 2024
Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for ImmunopreventionAna M Bolivar, Fahriye Duzagac, Nan Deng, et al.JCO Precision Oncology|March 9, 2022
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid TumorsPashtoon M Kasi, Gordon Fehringer, Hiroya Taniguchi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2023
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal CancerStefania Napolitano, Melanie Woods, Hey Min Lee, et al.Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerRyan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic targetGuo Chen, Nitin Chakravarti, Kimberly Aardalen, et al.Cancer Discovery|October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationDavid S Hong, Van K Morris, Badi El Osta, et al.Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal CancerMichael J Overman, Sara Lonardi, Ka Yeung Mark Wong, et al.Pageof 44